JP2023524808A5 - - Google Patents
Info
- Publication number
- JP2023524808A5 JP2023524808A5 JP2022567542A JP2022567542A JP2023524808A5 JP 2023524808 A5 JP2023524808 A5 JP 2023524808A5 JP 2022567542 A JP2022567542 A JP 2022567542A JP 2022567542 A JP2022567542 A JP 2022567542A JP 2023524808 A5 JP2023524808 A5 JP 2023524808A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical preparation
- abiraterone acetate
- niraparib
- treatment
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20173749 | 2020-05-08 | ||
| EP20173749.1 | 2020-05-08 | ||
| US202163142919P | 2021-01-28 | 2021-01-28 | |
| US63/142,919 | 2021-01-28 | ||
| US202163174282P | 2021-04-13 | 2021-04-13 | |
| US63/174,282 | 2021-04-13 | ||
| PCT/EP2021/062186 WO2021224469A1 (en) | 2020-05-08 | 2021-05-07 | Treatments of prostate cancer with combinations of abiraterone acetate and niraparib |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023524808A JP2023524808A (ja) | 2023-06-13 |
| JP2023524808A5 true JP2023524808A5 (https=) | 2024-05-10 |
Family
ID=75888052
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567542A Pending JP2023524808A (ja) | 2020-05-08 | 2021-05-07 | アビラテロン酢酸エステル及びニラパリブの組み合わせでの前立腺癌の治療 |
| JP2022567447A Pending JP2023525026A (ja) | 2020-05-08 | 2021-05-07 | 酢酸アビラテロン及びニラパリブの医薬製剤 |
| JP2022567451A Pending JP2023524794A (ja) | 2020-05-08 | 2021-05-07 | アビラテロン酢酸エステルとニラパリブの組み合わせによる前立腺癌の処置 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567447A Pending JP2023525026A (ja) | 2020-05-08 | 2021-05-07 | 酢酸アビラテロン及びニラパリブの医薬製剤 |
| JP2022567451A Pending JP2023524794A (ja) | 2020-05-08 | 2021-05-07 | アビラテロン酢酸エステルとニラパリブの組み合わせによる前立腺癌の処置 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20230226080A1 (https=) |
| EP (3) | EP4146210A1 (https=) |
| JP (3) | JP2023524808A (https=) |
| KR (3) | KR20230008780A (https=) |
| CN (3) | CN115515584A (https=) |
| AU (5) | AU2021267146B2 (https=) |
| BR (3) | BR112022021732A2 (https=) |
| CA (3) | CA3177123A1 (https=) |
| CR (1) | CR20220588A (https=) |
| EC (1) | ECSP22085983A (https=) |
| IL (3) | IL297984B2 (https=) |
| JO (3) | JOP20220294A1 (https=) |
| MX (3) | MX2022014003A (https=) |
| PE (1) | PE20230830A1 (https=) |
| PH (3) | PH12022553029A1 (https=) |
| TW (3) | TWI905184B (https=) |
| UA (1) | UA130040C2 (https=) |
| UY (3) | UY39204A (https=) |
| WO (3) | WO2021224467A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3243120A1 (en) * | 2022-02-04 | 2023-08-10 | Janssen Pharmaceutica Nv | Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and changes in hormone receptor function (HRF) |
| WO2025027138A1 (en) * | 2023-08-02 | 2025-02-06 | Janssen Pharmaceutica Nv | Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2132449C (en) | 1992-03-31 | 2002-09-10 | Susan E. Barrie | 17 - substituted steroids useful in cancer treatment |
| JP2003104888A (ja) * | 2001-09-28 | 2003-04-09 | Taiyo Yakuhin Kogyo Kk | ジヒドロピリジン誘導体の錠剤 |
| BRPI0719236A2 (pt) * | 2006-10-13 | 2014-07-08 | Janssen Pharmaceutica Nv | Composições de carbamato de fenilalquila |
| JP4611444B2 (ja) | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール |
| KR101653548B1 (ko) | 2008-01-08 | 2016-09-02 | 머크 샤프 앤드 돔 리미티드 | 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염 |
| CN102026628A (zh) * | 2008-02-15 | 2011-04-20 | 太阳医药高级研发有限公司 | 具有降低崩裂效果的口服控释片剂 |
| CA2808501A1 (en) * | 2010-08-23 | 2012-03-01 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof |
| CN102743393A (zh) * | 2012-07-27 | 2012-10-24 | 海南盛科生命科学研究院 | 一种含有醋酸阿比特龙的药物组合物及制备工艺 |
| HK1213197A1 (zh) * | 2013-03-04 | 2016-06-30 | Vtv治疗有限责任公司 | 包括葡糖激酶活化劑的固體組合物及其製備和使用方法 |
| WO2015032873A1 (en) * | 2013-09-06 | 2015-03-12 | Synthon B.V. | High-load pharmaceutical compositions comprising abiraterone acetate |
| EP3160450A1 (en) * | 2014-06-30 | 2017-05-03 | Galenicum Health S.L. | Stable pharmaceutical compositions in the form of immediate release tablets |
| SG11201701139YA (en) * | 2014-09-18 | 2017-03-30 | Iceutica Inc | Abiraterone acetate formulation and methods of use |
| SG11201811564QA (en) * | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
| CN110944638A (zh) * | 2017-03-27 | 2020-03-31 | 特沙诺有限公司 | 尼拉帕尼组合物 |
| HUE060460T2 (hu) * | 2017-04-13 | 2023-03-28 | Janssen Pharmaceutica Nv | Niraparib, abirateron-acetát és prednizon prosztatarák kezelésére |
| TWI843707B (zh) * | 2017-09-26 | 2024-06-01 | 美商提薩羅有限公司 | 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物 |
| JOP20200072A1 (ar) * | 2017-10-11 | 2020-04-29 | Janssen Oncology Inc | طرق علاج سرطان البروستاتا من خلال إعطاء أسيتات الأبيراتيرون إلى جانب البريدنيزون مع المعالجة بحرمان الأندروجين |
| CA3098208A1 (en) * | 2018-04-26 | 2019-10-31 | Synthon B.V. | Tablet compositions comprising abiraterone acetate |
| CN113166071B (zh) | 2018-10-03 | 2025-03-21 | 特沙诺有限公司 | 尼拉帕利盐 |
-
2021
- 2021-05-07 TW TW110116507A patent/TWI905184B/zh active
- 2021-05-07 KR KR1020227042483A patent/KR20230008780A/ko active Pending
- 2021-05-07 UY UY0001039204A patent/UY39204A/es unknown
- 2021-05-07 BR BR112022021732A patent/BR112022021732A2/pt unknown
- 2021-05-07 TW TW110116509A patent/TWI894266B/zh active
- 2021-05-07 IL IL297984A patent/IL297984B2/en unknown
- 2021-05-07 PH PH1/2022/553029A patent/PH12022553029A1/en unknown
- 2021-05-07 MX MX2022014003A patent/MX2022014003A/es unknown
- 2021-05-07 JP JP2022567542A patent/JP2023524808A/ja active Pending
- 2021-05-07 WO PCT/EP2021/062180 patent/WO2021224467A1/en not_active Ceased
- 2021-05-07 WO PCT/EP2021/062186 patent/WO2021224469A1/en not_active Ceased
- 2021-05-07 US US17/998,202 patent/US20230226080A1/en active Pending
- 2021-05-07 EP EP21725098.4A patent/EP4146210A1/en active Pending
- 2021-05-07 AU AU2021267146A patent/AU2021267146B2/en active Active
- 2021-05-07 BR BR112022022590A patent/BR112022022590A2/pt active IP Right Grant
- 2021-05-07 CN CN202180033488.6A patent/CN115515584A/zh active Pending
- 2021-05-07 UY UY0001039201A patent/UY39201A/es unknown
- 2021-05-07 IL IL297991A patent/IL297991A/en unknown
- 2021-05-07 US US17/998,198 patent/US20230218640A1/en active Pending
- 2021-05-07 CA CA3177123A patent/CA3177123A1/en active Pending
- 2021-05-07 AU AU2021269115A patent/AU2021269115A1/en active Pending
- 2021-05-07 CA CA3177137A patent/CA3177137A1/en active Pending
- 2021-05-07 CN CN202180033482.9A patent/CN115515583A/zh active Pending
- 2021-05-07 JP JP2022567447A patent/JP2023525026A/ja active Pending
- 2021-05-07 UY UY0001039203A patent/UY39203A/es unknown
- 2021-05-07 JP JP2022567451A patent/JP2023524794A/ja active Pending
- 2021-05-07 PH PH1/2022/553013A patent/PH12022553013A1/en unknown
- 2021-05-07 EP EP21725101.6A patent/EP4146211A1/en active Pending
- 2021-05-07 UA UAA202204571A patent/UA130040C2/uk unknown
- 2021-05-07 EP EP21724665.1A patent/EP4146209A1/en active Pending
- 2021-05-07 PE PE2022002554A patent/PE20230830A1/es unknown
- 2021-05-07 MX MX2022014005A patent/MX2022014005A/es unknown
- 2021-05-07 IL IL297990A patent/IL297990A/en unknown
- 2021-05-07 PH PH1/2022/553030A patent/PH12022553030A1/en unknown
- 2021-05-07 CN CN202180033483.3A patent/CN115551506A/zh active Pending
- 2021-05-07 KR KR1020227042489A patent/KR20230008782A/ko active Pending
- 2021-05-07 MX MX2022014004A patent/MX2022014004A/es unknown
- 2021-05-07 CA CA3177094A patent/CA3177094A1/en active Pending
- 2021-05-07 WO PCT/EP2021/062188 patent/WO2021224471A1/en not_active Ceased
- 2021-05-07 BR BR112022022534A patent/BR112022022534A2/pt active IP Right Grant
- 2021-05-07 TW TW110116506A patent/TW202207925A/zh unknown
- 2021-05-07 AU AU2021266409A patent/AU2021266409A1/en active Pending
- 2021-05-07 KR KR1020227042495A patent/KR20230008783A/ko active Pending
- 2021-05-07 US US17/998,204 patent/US20230226081A1/en active Pending
- 2021-05-07 CR CR20220588A patent/CR20220588A/es unknown
-
2022
- 2022-11-01 JO JOJO/P/2022/0294A patent/JOP20220294A1/ar unknown
- 2022-11-01 JO JOJO/P/2022/0288A patent/JOP20220288A1/ar unknown
- 2022-11-01 JO JOJO/P/2022/0292A patent/JOP20220292A1/ar unknown
- 2022-11-08 EC ECSENADI202285983A patent/ECSP22085983A/es unknown
-
2025
- 2025-12-11 US US19/415,909 patent/US20260097048A1/en active Pending
-
2026
- 2026-03-23 AU AU2026202227A patent/AU2026202227A1/en active Pending
- 2026-03-25 AU AU2026202283A patent/AU2026202283A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6351597B2 (ja) | 非転移性去勢抵抗性前立腺癌の治療のための抗アンドロゲン剤 | |
| CN105705148A (zh) | 使用普那布林和紫杉烷的组合的癌症疗法 | |
| JP2023524808A5 (https=) | ||
| JP2023501457A5 (https=) | ||
| Liu et al. | New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma | |
| JP2023524794A5 (https=) | ||
| JP2023525026A5 (https=) | ||
| JP2005530735A (ja) | 癌の処置のための併用療法 | |
| Mu et al. | Transarterial chemoembolization combined with intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: a phase 2 study | |
| Yang et al. | Challenges of using high-dose fractionation radiotherapy in combination therapy | |
| WO2025007946A1 (zh) | 治疗前列腺癌的方法 | |
| McCain | Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options | |
| RU2706341C1 (ru) | Способ лечения неоперабельной аденокарциномы головки поджелудочной железы | |
| Comito et al. | Systemic and liver-directed therapies in metastatic uveal melanoma: State-of-the-art and novel perspectives | |
| Cosentini et al. | Case report: exceptional response to second line temozolomide therapy in a patient with metastatic adrenocortical carcinoma | |
| JP7198666B2 (ja) | 微小血管血流低減剤およびその利用 | |
| CN105663028B (zh) | 一种含去水卫矛醇的经直肠给药双层缓释栓剂 | |
| Kong et al. | Safety and efficacy of | |
| TW202029961A (zh) | Ar拮抗劑聯合parp抑制劑在製備治療前列腺癌的藥物中的用途 | |
| Deng¹ et al. | and GM-CSF in oligometastatic | |
| Lit et al. | complicating TP53 mutation treated successfully with | |
| Cherchenko et al. | INTRA-ARTERIAL CHEMOTHERAPY IN ADVANCED PANCREATIC CANCER: A LITERATURE REVIEW | |
| Bydder et al. | A controlled trial of misonidazole in the curative treatment of infiltrating bladder cancer | |
| Guangsheng et al. | Zhao Guangsheng1, Liu Song2, 3, Yin Shunhang1, Ding Zhongyi1, Tang Shunxiong1, Zhou Jun1 and Zhang Yuewei4 | |
| Guangsheng et al. | TACE combined with sorafenib induces complete remission in an elderly patient with hepatocellular carcinoma, hepatic venous tumor thrombus, and diffuse lung metastasis: a case study and literature review |